Hematology Market

Hematology Market Size (2023 to 2028)

The global hematology market is forecasted to grow at a healthy CAGR of 8.2% from 2023 to 2028. As a result, the market size is estimated to grow from USD 9.12 billion in 2023 to USD 13.52 billion by 2028.

Hematology Market Share Insights:

• Based on the product, the hematology analyzers segment dominated the market in 2022.
• Based on the application, the infectious disease segment had a significant market share in 2022.
• Based on the end-user, the hospital segment led the market in 2022.
• Geographically, the North American region held the leading global hematology market share in 2022.
• The European region occupied a substantial share of the worldwide market in 2022. 

Hematology is a medical science branch concerned with diagnosing, treating, and studying blood and disorders associated with blood. It includes treating blood disorders such as leukemia, malignancies, hemophilia, sickle-cell anemia, and lymphoma. Hematology refers to the scientific branch of the study of blood, its diseases, treatments, and malignancies, including hemophilia, blood clots, leukemia, lymphoma, myeloma, and sickle-cell anemia. Among the hematology procedures, blood count or CBC is categorized as the most common test. The blood chemistry test, blood enzyme test, and blood tests to assess heart disease risk are examples of some more tests.

Impact of COVID-19 on the global hematology market:

The siege of the pandemic all over the globe impacted many businesses worldwide. Furthermore, implementing the lockdown resulted in further hindrances to management, and production lines, thus disrupting supply and demand chains. COVID-19 has favored the hematology market growth. A positive effect was observed concerning the impact of covid-19 on the global hematology market due to frequent examination of patients' blood and utilizing hematology analyzers to test and monitor COVID-19. According to the International Journal of Laboratory Hematology, the specific tests following neutrophilia, leucocytosis, lymphopenia, and thrombocytopenia, played a significant role in findings in patients infected with the SARS-CoV-2 virus, thus becoming standard procedures, thereby providing a market for growth opportunities. COVID-19 infection primarily affects the respiratory system. The PCR tests are currently being used to detect an antigen's presence, with several stages at which errors may occur between sampling and analysis. The hematology analyzers help provide an accurate presentation of reactive lymphocytes that play a critical role in managing COVID-19 patients, which has accelerated the growth rate of the global hematology market. Some diagnoses of COVID-19 infection emphasize markers derived from the hematology laboratory; the U.S. and many other countries face a significant health concern with the coronavirus's current outbreak (COVID-19). However, COVID-19 has widened the growth scope for the global hematology market, and this market is expected to experience new growth heights soon.

MARKET DRIVERS:

The rising prevalence of blood disorders is majorly propelling the global hematology market growth.

Blood disorders have become a worldwide health issue with different causes and are related to high mortality. Blood disorders like anemia, blood cancer, hemorrhagic conditions, and blood infections affect people across all age groups annually. According to WHO, insufficient hemoglobin affects 75% of births globally, and sickle cell trait affects an estimated one in 12 African Americans. Over 70% of all sickle-cell-affected births occur in Africa. As per the WHO, the prevalence of anemia in children is 47% and 13% in men, and it is increasing rapidly worldwide. According to the National Institute of Health (NIH), anemia affects 29% of women of reproductive age and 38% of pregnant women worldwide.

The rising number of blood donation camps worldwide is a significant factor promoting the growth of the hematology market.

In addition, growing incidences of chronic diseases, the YOY rise in the geriatric population, and the increasing prevalence of point-of-care testing devices are anticipated to fuel the growth rate of the hematology market. Furthermore, with increasing support from the government through investments, people's interest in cost-effective diagnosis procedures favor the hematology market.

Due to the rising prevalence in the study of hematological malignancies, hemoglobinopathy, anemia, and coagulopathy, which are also regarded as the four main areas of study in hematology, as a result of increasing chronic disorders, it is expected to drive the hematology market. Among these, hemoglobinopathy is the most studied area, which involves the study of an abnormality in the globin chains of hemoglobin molecules, including sickle cell anemia and thalassemia, which are a part of hemoglobinopathy.

There has been a rise in hematologists globally due to their excellent counseling to patients, working closely with experts from various medical and surgical specialties, most commonly with oncologists, to provide intense care to adults and children for cancers of blood and bone marrow, leukemia, and lymphoma. They are also usually associated with pathologists, called hematopathologists or hematopathologists through specialization in diagnosing hematological diseases, who work together with hematologists to formulate diagnoses, such as for the treatment of bleeding disorders hemophilia and idiopathic thrombocytopenic purpura, treatment of hematological malignancies, and the treatment of hemoglobinopathies bone marrow and stem cell transplantation. These factors are leading to the drive of the hematology market.

MARKET RESTRAINTS:

However, the need for sufficient knowledge of the devices in rural areas is slowly hindering the growth of the hematology market. In addition, the high cost of installing and maintaining the equipment, especially in laboratories, is challenging for the hematology market.

REPORT COVERAGE:

The research report on the global hematology market has been segmented and sub-segmented based on the product, application, end-user, and region.

Hematology Market – By Product:

• Hematology Analyzers
• Hematology Reagents
• Flow Cytometers
• Hematology Cell Counters
• Slide Stainers
• Coagulation Analyzers
• Hematology Testing
• Centrifuges
• Hemoglobinometers
• Others

Based on the product, the hematology analyzers segment is the most promising and expected to register a healthy growth rate during the forecast period. Increasing incidences of road accidents due to a rise in the demand to store blood, which can be used in emergencies, significantly influences the market's growth. Hematology analyzers are used in the medical field to perform tests on blood samples for complete blood counts, coagulation tests, white blood cell counts, and reticulocyte analyses, which is helpful for research laboratories and veterinarians. Some allow choosing the preferred test type; others consider sample size, speed, type, and the number of test modes. They are called cell counters due to the counting of hematocrit and hematocrit levels, along with CBC.

The hematology cell counters segment is anticipated to account for a substantial market share during the forecast period owing to their wide adoption for diagnosing and monitoring most blood-related disorders. It is also called CBC and involves drawing blood by inserting a needle into a vein to let it into a tube.

The hemoglobinometers segment is foreseen to register a steady CAGR during the forecast period. These are used as a standard method for measuring the hemoglobin content of the blood. This device compares the color through light bypass over a hemolyzed blood sample.

Hematology Market - By Application:

• Infectious Diseases
• Cancer
• Cardiovascular Disorders
• Blood Screening
• Diabetes
• HIV
• Auto-Immune Diseases

Based on the application, the infectious disease segment is predicted to lead the global hematology market during the forecast period due to the increasing incidences of various health disorders. Also, the rise in healthcare centers' spending further accelerates the segment's growth.

The cancer segment is anticipated to hold a substantial share of the global hematology market during the forecast period owing to rising cancer cases, leading to hematological oncologists growth, which specializes in hematology, the study of blood, and oncology, the study of cancer, for treatment, diagnosis, and prevention of blood cancers and blood-related disorders.

The CVDs segment is also expected to register healthy growth during the forecast period. Cardiovascular disorders are rising, leading to the expectation of high growth in this segment. This led to creating new and exciting fields, cardio-oncology and cardio-hematology, attracted by amyloidosis with clonal hematopoiesis of undetermined potential.

Hematology Market - By End-User:

• Hospitals
• Clinics
• Diagnostic Laboratories
• Research and Development Centers
• Others

Based on the end-user, the hospital end-user segment is forecasted to dominate the global hematology market during the forecast period. The growing constructional activities of hospitals due to the increasing flow of patients with varied diseases are accelerating the market's growth. In addition, the rising prevalence of minimally invasive surgeries to cure the conditions more effectively with available treatment options is ascribed to bolstering the growth of the hematology market.

The clinics segment is foreseen to project a healthy CAGR during the forecast period. Clinical hematology laboratories are widely used in performing various basic and advanced hematology tests on serum, whole blood, cerebrospinal fluid, urine, and other bodily fluids.

The diagnostic laboratories segment is anticipated to register a steady CAGR during the forecast period. Diagnostic laboratories help perform advanced hematology testing using advanced techniques like flow cytometry-based methods and electrophoresis.

Hematology Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The North American hematology market accounted for the largest share of the global hematology products and services market in 2022, followed by Europe. Some factors, such as the rising incidence of patients suffering from blood disorders, the high number of patients with blood coagulation disorders, the growing prevalence of target diseases, and blood transfusions, are increasing hematology testing in North America.

On the other hand, the Europe hematology market is predicted to have a healthy CAGR in the coming years. In addition, the rise in per capita income leading to an increase in the adoption of therapy products and diagnostics coupled with government initiatives to improve healthcare infrastructure are expected to fuel the regional market growth. Europe has been growing faster in past years and will continue to have the same growth rate in foreseen years. Furthermore, replacing traditional testing devices with modern devices broadens the market's demand.

Following North America, the Asia pacific hematology market is anticipated to register the fastest CAGR during the forecast period. The increasing population and rising awareness of over-utilizing the latest technology are leveraging this market's growth in this region.

The Latin American hematology market is anticipated to grow steadily during the forecast period.

The Middle East and Africa hematology market is deemed to have an inclined growth rate soon.

KEY MARKET PARTICIPANTS:

Some of the major companies dominating the global hematology market profiled in this report are Siemens AG Healthcare, Johnson & Johnson, Beckman Coulter, Inc., Abbott Laboratories, Thermo Fisher Scientific, Roche, HORIBA Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc., Boule Diagnostics AB, Mindray Medical International Limited.

RECENT MARKET HAPPENINGS:

• In November 2022, EKF Diagnostics, a global in vitro diagnostics company, improved DiaSpect Tm for its connection with the newly released EKF Link analyzer for ensuring securely stored and accessible test results, which is now also equipped with Bluetooth and internal storage to provide a calculated hematocrit value with the usual hemoglobin result.
• In November 2022, according to data from a phase 1 study by Society for Immunotherapy on cancer, the first personalized cell therapy was shown to be safe in solid tumors using gene replacement, which also led the researchers to find a higher frequency of transgenic neo-antigen compared to the pre-infusion level of wild-type TCRs, in post-infusion tumor biopsies.
• In June 2018, the partnership between Beckman Coulter Diagnostics and the University of California fuelled the research measures in hematology and supported innovative products.
• In May 2018, Beckman Coulter launched the DxH 900 hematology analyzer, which performs complete blood count and white blood cell differential tests in clinical laboratories with minimal repeats.
• In March 2018, the Cobas m 511 integrated hematology analyzer was developed by Cobas and Roche Diagnostics Hematology, Inc. and received approval from the FDA (Food and Drug Administration). A digital morphology analyzer, cell counter, and classifier are integrated into a streamlined instrument for preparing, staining, and analyzing microscopy blood slides.
• The Yumizen G ranges from semi to fully Horiba launched automated hemostasis solutions in February 2018, which this product has strengthened the company's position in the market.
• In January 2018, Abbott's launch of an h-series integrated hematology system brought several changes to clinical laboratories.   
• In November 2017, New Automated Hematology Analyzer was introduced with the acquisition of Sysmex and CLIA Wavier. It helped the company to have a good market position in recent years.
• In April 2017, Sysmex launched XN Series Automated Hematology Analyzers to provide adequate end-user services.